The IMITHEA Group and Roche Diagnostics Hellas are joining forces in a strategic partnership that sets new standards in laboratory testing and the broader field of diagnostics in Greece.
Through this partnership, Roche Diagnostics, a global leader in diagnostic solutions, is living its mark on the complete modernization of the central laboratories at Henry Dunant Hospital Center and at the Group’s hospital facilities in Thessaloniki—General Clinic, Kyanous Stavros and Genesis General Clinic—as well as Rhodes General Clinic and Kozani General Clinic, key pillars of the IMITHEA Group’s network, with cutting-edge technology and latest-generation reagents, enhancing the healthcare services provided through the integration of advanced diagnostic solutions. These internationally recognized systems meet the most demanding laboratory accreditation requirements across the full range of biochemical, immunological and hematological tests.
Commenting on the partnership, Themos Charamis, Executive Chairman of the Imithea Group, said: “Quality and safety are core priorities for Henry Dunant Hospital Center and the IMITHEA Group, guiding every step we take and ensuring that our patients always have access to the most advanced and reliable diagnostic tools. Our partnership with Roche Diagnostics, a global leader in diagnostic technology, reaffirms our commitment to high-quality healthcare services, reinforces our shared vision, and lays the foundation for new, innovative, and pioneering advances in healthcare.”
For his part, Siete Braak, CEO of Roche Diagnostics Hellas, stressed: “Our partnership with the IMITHEA Group is setting new standards for the quality of healthcare in Greece. Supporting 70% of clinical decisions throughout the patient journey, diagnostic testing plays a pivotal role in disease prevention, early diagnosis, and disease management, while also contributing to the development of more sustainable healthcare systems. Roche Diagnostics provides access to advanced diagnostic tools and testing drawing on its global expertise and investing in meaningful partnerships. By joining forces with the IMITHEA Group, we are making modern, reliable, and innovative solutions available to patients—solutions that can transform not only their healthcare experience but their lives as well.
The IMITHEA Group's strategic partnership with Roche Diagnostics Hellas further strengthens patient care by providing access to the most reliable diagnostic solutions, while equipping healthcare professionals with high-value medical insights essential for making faster and more accurate decisions—reducing the burden of disease in critical areas such as cardiometabolic diseases, neurological disorders, cancer, and infectious diseases. This, in turn, helps transform the patient journey while delivering better health outcomes.
About IMITHEA Group
The IMITHEA Group operates a strong healthcare network comprising six General Clinics—Henry Dunan Hospital in Athens, Kyanous Stavros General Clinic and General Genesis Clinic in Thessaloniki, General Clinic in Rhodes, and General Clinic in Kozani—along with a state-of-the-art Rehabilitation Center (Arogi, in Pylaia, Thessaloniki) and a pioneering Assisted Reproduction Unit (IVF Fertilia, in Thessaloniki). Together, these facilities form one of the fastest-growing pillars of private healthcare in Greece. The Group has a total capacity of 1,360 inpatient beds, collaborates with more than 3,300 physicians across all specialties, and serves over 600,000 patients annually.
About Roche
Roche is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
The company was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 100 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focused on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com, www.roche.gr
All trademarks used or mentioned in this release are protected by law.
* Pictured: Themos Charamis, Executive Chairman of the IMITHEA Group, and Siete Braak, CEO of Roche Diagnostics Hellas (right), marking the strategic partnership.
